LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

CerTest to Run ‘More than Diagnostics’ Campaign Throughout 2023

By LabMedica International staff writers
Posted on 01 Feb 2023
Print article
Image: The ‘More than Diagnostics’ campaign expresses the company’s ambition to continue growing and advancing towards an exciting future (Photo courtesy of CerTest)
Image: The ‘More than Diagnostics’ campaign expresses the company’s ambition to continue growing and advancing towards an exciting future (Photo courtesy of CerTest)

The world is currently experiencing a change of era. Even as it still emerging from the SARS-CoV-2 pandemic, there are new unexpected challenges that must be met. For CerTest Biotec (Zaragoza, Spain), the recent years of the pandemic have been a turning point that have made it a better company in every sense. CerTest has demonstrated that under extreme conditions, it has the ability to work towards achieving a common goal, offer a befitting response to the extraordinary circumstances and, instill confidence among its customers, suppliers and partners.

CerTest has now announced that the company will run its campaign ‘More than Diagnostics’ throughout 2023 in acknowledgement of the transformation that it has gone through, accelerated by the COVID-19 pandemic. CerTest’s ‘More than Diagnostics’ campaign expresses the company’s ambition to continue growing and advancing towards an exciting future, with people’s health remaining its key focus.

CerTest remains optimistic about the future and is well aware of the need to sustain its efforts and to continue backing the four concepts which have defined the company right from the start - service, responsibility, confidence and research. Over the coming period, CerTest plans to employ more people, build more facilities, increase its R&D activities, and come up with more products and solutions that are better as well as more effective.

Related Links:
CerTest Biotec 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more